Literature DB >> 33334956

Henoch-Schönlein purpura in children: Use of corticosteroids for prevention and treatment of renal disease.

Amir Gohari, Douglas G Matsell, Cherry Mammen, Ran D Goldman.   

Abstract

QUESTION: A few patients have previously presented to my clinic with palpable purpura, joint inflammation, and severe abdominal pain characteristic of Henoch-Schönlein purpura (HSP). Considering that renal injury is the primary long-term complication of HSP, are corticosteroids effective in preventing or treating renal disease in children with HSP? ANSWER: Henoch-Schönlein purpura is self-limiting in 94% of children, but permanent renal injury is reported in one-fifth of children with nephritic or nephrotic features. Corticosteroids have been considered as candidates for preventing and treating renal involvement in HSP. There is a moderate level of evidence to suggest corticosteroids are not effective in preventing renal involvement in HSP. However, based on low-level evidence and similarities with primary immunoglobulin A nephropathy, experts recommend corticosteroids in treating renal involvement in HSP to prevent long-term kidney injury. Dose and duration of therapy should be carefully considered in consultation with a pediatric nephrologist.
Copyright © the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33334956      PMCID: PMC7745939          DOI: 10.46747/cfp.6612895

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  25 in total

1.  Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.

Authors:  Janet M M Gardner-Medwin; Pavla Dolezalova; Carole Cummins; Taunton R Southwood
Journal:  Lancet       Date:  2002-10-19       Impact factor: 79.321

2.  Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura.

Authors:  F Mollica; S Li Volti; R Garozzo; G Russo
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

3.  Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura.

Authors:  Evangéline Pillebout; Corinne Alberti; Loic Guillevin; Amel Ouslimani; Eric Thervet
Journal:  Kidney Int       Date:  2010-05-26       Impact factor: 10.612

4.  Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis.

Authors:  Jean-Claude Davin; Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

5.  Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial.

Authors:  Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Marjatta Antikainen; Jussi Merenmies; Jukka Rajantie; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

Review 6.  Immunoglobulin A Nephropathy and Immunoglobulin A Vasculitis.

Authors:  Oana Nicoara; Katherine Twombley
Journal:  Pediatr Clin North Am       Date:  2019-02       Impact factor: 3.278

7.  Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide.

Authors:  Penina Tarshish; Jay Bernstein; Chester M Edelmann
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

8.  Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis.

Authors:  Han Chan; Yan-Ling Tang; Xiao-Hang Lv; Gao-Fu Zhang; Mo Wang; Hai-Ping Yang; Qiu Li
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 9.  Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

10.  Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center.

Authors:  Vanesa Calvo-Río; Javier Loricera; Cristina Mata; Luis Martín; Francisco Ortiz-Sanjuán; Lino Alvarez; M Carmen González-Vela; Domingo González-Lamuño; Javier Rueda-Gotor; Héctor Fernández-Llaca; Marcos A González-López; Susana Armesto; Enriqueta Peiró; Manuel Arias; Miguel A González-Gay; Ricardo Blanco
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.